<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Propanc Biopharma, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock</link>
<description>Latest news and press releases for Propanc Biopharma, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/propanc-biopharma-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo695e569d905484111c2fed56.webp</url>
<title>Propanc Biopharma, Inc. Common Stock</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock</link>
</image>
<item>
<title>Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-executes-multi-yr-anti-aging-and-cancer-research-collaboration-with-the-universities-of-jaen-and-granada-spain</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-executes-multi-yr-anti-aging-and-cancer-research-collaboration-with-the-universities-of-jaen-and-granada-spain</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Fifth Agreement between Propanc & the Universities over a 17yr Period MELBOURNE, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc.</description>
</item>
<item>
<title>Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-targets-dollar3b-pancreatic-cancer-market-with-prp-85percent-tumor-inhibition-in-breakthrough-proenzyme-therapy-22</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-targets-dollar3b-pancreatic-cancer-market-with-prp-85percent-tumor-inhibition-in-breakthrough-proenzyme-therapy-22</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Root-Cause Attack. Chemo Sensitization. Safer Profile. MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB)</description>
</item>
<item>
<title>Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-executes-service-agreement-with-fyonibio-to-establish-and-validate-pharmacokinetics-assay-for-phase-1b-first-in-human-study-20</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-executes-service-agreement-with-fyonibio-to-establish-and-validate-pharmacokinetics-assay-for-phase-1b-first-in-human-study-20</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc</description>
</item>
<item>
<title>Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharmas-lead-asset-prp-shows-greater85percent-tumor-growth-inhibition-in-preclinical-pancreatic-models</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharmas-lead-asset-prp-shows-greater85percent-tumor-growth-inhibition-in-preclinical-pancreatic-models</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc.</description>
</item>
<item>
<title>Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-provides-corporate-update-and-reports-half-yearly-202526-results</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-provides-corporate-update-and-reports-half-yearly-202526-results</guid>
<pubDate>Wed, 18 Feb 2026 13:45:00 GMT</pubDate>
<description>MELBOURNE, Australia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported half yearly financial results as of December 31, 2025 (Year end June 30). Corporate and R&D Highlights Accelerates IP Momentum: Files Four Provisional Patent Applications – Strengthening Global Protection for Breakthrough</description>
</item>
<item>
<title>Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-unveils-prp-game-134500094</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-unveils-prp-game-134500094</guid>
<pubDate>Thu, 05 Feb 2026 13:45:00 GMT</pubDate>
<description>MELBOURNE, Australia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas of high unmet need such as pancreatic cancer. PRP is a propriet</description>
</item>
<item>
<title>Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-accelerates-ip-momentum-134500611</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-accelerates-ip-momentum-134500611</guid>
<pubDate>Tue, 27 Jan 2026 13:45:00 GMT</pubDate>
<description>Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer PreventionMELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the filing of its fourth new provisional patent application in the past two</description>
</item>
<item>
<title>Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-files-provisional-patent-134500344</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-files-provisional-patent-134500344</guid>
<pubDate>Tue, 20 Jan 2026 13:45:00 GMT</pubDate>
<description>A World-First, Fully Synthetic Recombinant Version of PRPMELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia. The patent application describes an optimized</description>
</item>
<item>
<title>Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-explains-prp-could-134500983</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-explains-prp-could-134500983</guid>
<pubDate>Thu, 15 Jan 2026 13:45:00 GMT</pubDate>
<description>The Science, Clinical Promise, & Market OutlookMELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the latest update on pancreatic cancer research. Pancreatic cancer remains one of the most lethal human malignancies: median survival after diagnosis is typically measured in month</description>
</item>
<item>
<title>Propanc Biopharma Provides Shareholder Update</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-provides-shareholder-134500851</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-provides-shareholder-134500851</guid>
<pubDate>Tue, 13 Jan 2026 13:45:00 GMT</pubDate>
<description>CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced a shareholder update from its Chief Executive Officer and Cofounder, Mr. James Nathanielsz. In this update, Mr. Nathanielsz highlights the signific</description>
</item>
<item>
<title>Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-publishes-impact-proenzymes-120000565</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-publishes-impact-proenzymes-120000565</guid>
<pubDate>Mon, 22 Dec 2025 12:00:00 GMT</pubDate>
<description>Results Underscore PRP Candidacy as a Disruptor of the Tumor MicroenvironmentMELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer reviewed journal, Scientific Reports, rega</description>
</item>
<item>
<title>Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-investigates-mesenchymal-drift-134500554</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-investigates-mesenchymal-drift-134500554</guid>
<pubDate>Thu, 04 Dec 2025 13:45:00 GMT</pubDate>
<description>Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central RoleMELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced plans to investigate the phenomenon of “mesenchymal drift”—an emerging area of research that may help unlock the mechanisms behind the reversal of chronic</description>
</item>
<item>
<title>Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-requests-foreign-filing-134500455</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-requests-foreign-filing-134500455</guid>
<pubDate>Mon, 01 Dec 2025 13:45:00 GMT</pubDate>
<description>MELBOURNE, Australia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted a request for a foreign filing license from Spain for two provisional patents detailing new methods to treat resistant cancer and fibrosis. The patents will be filed with IP Australia under Propanc Pty Ltd, the Company’s wholly owned operating</description>
</item>
<item>
<title>Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-provides-corporate-reports-134500305</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-provides-corporate-reports-134500305</guid>
<pubDate>Mon, 17 Nov 2025 13:45:00 GMT</pubDate>
<description>MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results for the first quarter ended September 30, 2025 (Year end June 30). Corporate and R&D Highlights Advancing PRP Toward Phase 1b First-in-Human Trial (2026) Propanc continues to advance its lead candidate,</description>
</item>
<item>
<title>Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-inc-secures-up-to-dollar100-million-private-placement-to-support-digital-asset-acquisition-strategy-and-accelerate-companys-randd-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-inc-secures-up-to-dollar100-million-private-placement-to-support-digital-asset-acquisition-strategy-and-accelerate-companys-randd-pipeline</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Initial Investment of $1 Million Received from Hexstone Capital LLC Upon Closing MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma,</description>
</item>
<item>
<title>Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-inc-pursues-strategic-acquisition-plan-targeting-digital-asset-treasury-dat-companies-trading-below-market-cap-to-net-asset-value-mnav</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-inc-pursues-strategic-acquisition-plan-targeting-digital-asset-treasury-dat-companies-trading-below-market-cap-to-net-asset-value-mnav</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company</description>
</item>
<item>
<title>CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/correction-propanc-biopharma-announces-strategic-financing-agreement-of-up-to-dollar100-million-with-hexstone-capital</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/correction-propanc-biopharma-announces-strategic-financing-agreement-of-up-to-dollar100-million-with-hexstone-capital</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 MELBOURNE, Australia, Oct. 15, 2025</description>
</item>
<item>
<title>Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-announces-strategic-financing-agreement-of-up-to-dollar100-million-with-hexstone-capital</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-announces-strategic-financing-agreement-of-up-to-dollar100-million-with-hexstone-capital</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 MELBOURNE, Australia, Oct. 15, 2025</description>
</item>
<item>
<title>Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-reports-end-of-fiscal-year-highlights-and-outlines-therapeutic-development-and-dollar100m-digital-asset-treasury-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-reports-end-of-fiscal-year-highlights-and-outlines-therapeutic-development-and-dollar100m-digital-asset-treasury-strategy</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company</description>
</item>
<item>
<title>Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office</title>
<link>https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-receives-certificate-grant-124500291</link>
<guid isPermaLink="true">https://6ix.com/company/propanc-biopharma-inc-common-stock/news/propanc-biopharma-receives-certificate-grant-124500291</guid>
<pubDate>Wed, 17 Sep 2025 12:45:00 GMT</pubDate>
<description>Fourth US Granted Patent Captures Claims for Future Clinical Dose of PRPMELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s “proenzyme composition” patent was received from the US Patent & Trademark Office (USPTO). The patent specifically c</description>
</item>
</channel>
</rss>